A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors

Inclusion criteria

• Able to understand and willing to sign the ICF.
• Adults 18 years of age or older.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Life expectancy at least 12 weeks.
• Adequate organ and bone marrow function.

Eligibility Criteria：

• Previous exposure to any anti-TIGIT antibody.
• Participate in another interventional clinical study, except for the observational (non-interventional) clinical study or the survival follow-up phase of the interventional study.
• Any investigational drugs received within 4 weeks prior to the first study treatment.
• Receive the last dose of anti-tumor therapy within 4 weeks before the first dose of study therapy.
• Immunosuppressive drugs were used within 4 weeks prior to the first administration of the study drug.
• Medication requiring long-term systemic hormones or any other immunosuppression therapy.
• Major surgical procedures (craniotomy, thoracotomy, or laparotomy) or unhealed wounds, ulcers, or fractures were performed within 4 weeks prior to the first dose of study therapy.
• Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases, or leptomeningeal disease.
• History of autoimmune disease , present active autoimmune disease or inflammatory diseases
• Positive human immunodeficiency virus (HIV) test.
• Active hepatitis B or C, or tuberculosis.
• History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
• Known history of hypersensitivity to any components of the IBI939 or Sintilimab.
• Pregnant or nursing females.